Replies to post #81561 on Biotech Values

[DewDiligence]

TEVA BIIB ELN:

But if u look at just the last couple quarters... Tysabri is superior :)

Actually, it wasn’t. Referring to the table in #msg-39941769: in the past two quarters, the cumulative growth of US Tysabri sales was 8.7% while the cumulative growth of US Copaxone sales was 14.1%.